| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
|
N Engl J Med
|
2006
|
34.52
|
|
2
|
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
|
N Engl J Med
|
2002
|
24.87
|
|
3
|
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
12.54
|
|
4
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
11.98
|
|
5
|
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2016
|
6.84
|
|
6
|
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
|
Lancet
|
2015
|
5.42
|
|
7
|
Cancer Statistics, 2017.
|
CA Cancer J Clin
|
2017
|
4.77
|
|
8
|
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
|
Lancet
|
2014
|
4.75
|
|
9
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
|
J Clin Oncol
|
2008
|
3.83
|
|
10
|
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
|
Lancet
|
2016
|
2.25
|
|
11
|
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
1.81
|
|
12
|
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
|
Lancet Oncol
|
2016
|
1.77
|
|
13
|
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
|
J Clin Oncol
|
2009
|
1.54
|
|
14
|
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
|
Eur Urol
|
2014
|
1.50
|
|
15
|
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
|
Mol Ther
|
2010
|
1.23
|
|
16
|
Chemoimmunotherapy: reengineering tumor immunity.
|
Cancer Immunol Immunother
|
2013
|
1.11
|
|
17
|
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
|
Cancer
|
2014
|
0.95
|
|
18
|
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.90
|
|
19
|
Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
|
J Immunol
|
2009
|
0.84
|
|
20
|
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
|
Proc Natl Acad Sci U S A
|
2017
|
0.76
|
|
21
|
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
|
Lung Cancer
|
2017
|
0.75
|
|
22
|
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2017
|
0.75
|
|
23
|
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
|
Dis Markers
|
2016
|
0.75
|